PLGA-PEG

Nanoprecipitation

Docetaxel

-

LNCaP

80-200

-

[123]

PLGA-PEG

Nanoprecipitation

Cisplatin

-

LNCaP, PC3

(131 ± 0.5) - (172 ± 3.4)

-

[124]

PLGA-PEG

Emulsion-solvent evaporation

Conjugated peptide, Coumarin-6

-

bEnd.3

(104.17 ± 3.45) - (121.46 ± 0.76)

(−24.43 ± 0.22) - (−18.25 ± 0.88)

[125]

PLGA-PEG

Modified double emulsion

Cisplatin

Sodium Cholate

LNCaP

(134.3 ± 5.2) - (159.8 ± 6.2)

(−5.7) - (−9.3)

[126]

PLGA-PEG

Solvent-diffusion

Doxorubicin

PEMA

MDA-MB-231, B16F10, MCF-7

(366.6 ± 3.1) - (423.0 ± 16.6)

(−18.9 ± 2.4) - (−51.7 ± 3.1)

[127]

PLGA-PEG

Nanoprecipitation

Paclitaxel

-

HUVEC

(114 ± 3) - (146 ± 2)

(−0.36 ± 4.3) - (0.12 ± 3.6)

[128]

PLGA-PEG

Solvent evaporation

Paclitaxel

PVA

JC, NCI/ ADR-RES or MCF-7

(221 ± 5) - (240 ± 1)

(−18 ± 5) - (−35 ± 5)

[129]

PLGA-PEG

Nanoprecipitation

Docetaxel

-

LNCaP

(153.3 ± 13.9)

−42 ± 1

[130]

PLGA?PEG

Emulsion-solvent diffusion

Docetaxel

PVA

SKOV3

(120 ± 5) - (216 ± 18)

(−6.27 ± 0.95) - (−12.2 ± 0.6)

[131]

PLGA-PEG-Aptamer

Nanoprecipitation

Docetaxel

-

LNCaP, PC3

(160 ± 3.7) - (291 ± 5.2)

(−20) - (−29)

[132]

PLGA-PEI

Solvent displacement

Plasmid DNA

Poloxamer-188

Calu-3

207 - 231

(32.1 ± 6.7) - (58.8 ± 4)

[133]

PLGA-PEI

Solvent evaporation

Paclitaxel

PVA

JC

(228 ± 22) - (237 ± 16)

(−12.1 ± 0.3) - (−24.0 ± 0.5)

[134]

PLGA-TPGS

Solvent extraction/ evaporation

Docetaxel

TPGS

Caco-2, MCF-7

(219.42 ± 5.24) - (253.51 ± 5.38

(−21.87 ± 2.11) - (34.1 ± 4.28)

[135]

PLGA-TPGS

Solvent extraction/ evaporation

Doxorubicin

-

MCF-7, C6 glioma

(324 ± 5) - (359 ± 10)

-

[136]

PLGA-TPGS)

Modified solvent extraction/ evaporation

Docetaxel, Coumarin-6

TPGS

HeLa

(207.15 ± 8.46) - (290.25 ± 7.64)

(−15.22 ± 2.21) - (−32.10 ± 0.65)

[137]

PMB, PMBH

Emulsion-solvent evaporation

Doxorubicin, Paclitaxel

-

HeLa

242 ± 10, 218 ± 9

−2.0 ± 0.5, −2.0 ± 0.6

[138]

Poly (ethylene oxide)- modified poly (beta-amino ester)

Solvent evaporation

Paclitaxel,

-

SKOV-3

60 - 150

40

[139]

Poly (β-amino esters) {Arg-Gly-Asp (RGD) peptide coated}

Electrostatic self-assembly

DNA

-

HUVEC

200

−5

[140]

Poly (β-malic acid)

-

Antisense oligonucleotides

-

U87MG, TG98, MDA MB-231.

6.6 - 24

(−27 ± 1) - (−5.2 ± 0.4)

[141]

Poly (β-malic acid)

-

Antisense oligonucleotides

-

BT-474, SKBR-3, MDA-MB-231, MDA- MB-435, MDA-MB-468, MCF-7

(15.1 ± 1.2) - (22.1 ± 2.3)

(−4.1 ± 0.4) - (−5.7 ± 0.6)

[142]

Poly (γ-glutamic acid)-Poly (lactide)

Emulsion-solvent evaporation

Paclitaxel

-

HepG2

(115.4 ± 4.2) - (263.2 ± 6.8)

(−19.2 ± 2.2) - (−22.5 ± 3.2)

[143]

PS (Carboxyl- modified fluorescent)

Commercial

-

Commercial

HeLa, HUVEC

24 ± 4, 43 ± 6

-

[25] [144]

β-Cyclodextrin (Transferrin conjugated)

Polycondensation

DNA

-

PC-3, K562

100 - 150

15

[145]